China’s NMPA approved two differentiated therapies: Cardamyst, a self-administered nasal spray for paroxysmal supraventricular tachycardia from Everest Medicines, and Yingmule, a long-acting RSV monoclonal antibody from Simcere Pharmaceutical for prevention of RSV-related lower respiratory tract infections in newborns and infants. The dual approvals underscore the agency’s continued push for differentiated delivery approaches across both acute cardiovascular episodes and pediatric infectious disease prevention. For biotech companies, the RSV approval also reinforces the importance of long-acting biologics in seasonal respiratory disease prevention in early life, where hospitalization and healthcare burden remain high.